Analysis of early haematological warning indicators for drug-resistant Mycoplasma pneumoniae infection
- 1Department of Pediatrics, The Fourth Affiliated Hospital of Soochow University, Suzhou, China
Abstract
Objective: This study aimed to investigate the haematological changes in children with Mycoplasma pneumoniae (MP) infection carrying the 2063/2064 mutation, providing a clinical reference for the early identification of drug-resistant MP.
Methods: A retrospective study was conducted on 161 children diagnosed with MP infection via nucleic acid testing in our hospital in 2024, alongside 27 healthy controls. Based on the 2063/2064 mutation status, the MP group was divided into a mutation-undetected group (n = 27) and a mutation-detected group (n = 134). Haematological parameters and inflammatory indices at diagnosis were compared. Dynamic changes between the initial visit and diagnosis were analysed in 64 mutation-detected patients with complete paired data. Additional analyses included bootstrap resampling, post-hoc power assessment, exploratory ROC analysis, logistic regression and hospitalisation-stratified sensitivity analysis.
Results: No significant differences were observed between the mutation-detected and mutation-undetected groups in clinical characteristics or haematological and inflammatory indices at diagnosis (all p > 0.05). Among the 64 mutation-detected patients with complete paired measurements, MLR decreased from 0.32 (0.24, 0.48) at the initial visit to 0.27 (0.19, 0.37) at diagnosis (p = 0.004). In the hospitalisation-stratified analysis, this decline was significant among hospitalised patients but not among non-hospitalised patients. Exploratory ROC analysis showed limited discriminatory performance for both the directional MLR change (AUC = 0.508, 95% CI 0.344–0.672) and its absolute magnitude (AUC = 0.523, 95% CI 0.349–0.699).
Conclusion: Static haematological parameters and inflammatory indices did not distinguish mutation-detected from mutation-undetected MP infection. Although MLR decreased over time in the mutation-detected subgroup, ROC and stratified analyses showed that this change had limited discriminatory performance when used alone and may have been influenced by hospitalisation-related clinical factors. Dynamic MLR change should therefore be considered an exploratory marker requiring prospective validation.
Related
- Epidemiological Characteristics and Clinical Impact of Macrolide‐Resistant Mycoplasma pneumoniae Infection in Children in Southwest China, 2021–2025
- Early diagnosis of Mycoplasma pneumoniae pneumonia: Development and validation of a predictive model based on clinical examination indicators
- Emergence of Novel Macrolide-Resistant Mycoplasma pneumoniae Sequence Type 3 Subclades in Children after COVID-19 Pandemic, Taiwan
- Prevalence and Treatment of Macrolide-Resistant Mycoplasma pneumoniae Infections in Singapore
- Etiological characteristics and genotypes of Mycoplasma pneumoniae infection in children in Baoding from 2022 to 2024
BibTeX
@article{yang2026analysis,
title = {{Analysis of early haematological warning indicators for drug-resistant Mycoplasma pneumoniae infection}},
author = {Yuanyuan Yang and Tao Sun and Changyu Fu and Xiaofang Yan},
journal = {Frontiers in Pediatrics},
year = {2026},
month = oct,
doi = {10.3389/fped.2026.1854263},
url = {https://doi.org/10.3389/fped.2026.1854263},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Analysis of early haematological warning indicators for drug-resistant Mycoplasma pneumoniae infection
AU - Yuanyuan Yang
AU - Tao Sun
AU - Changyu Fu
AU - Xiaofang Yan
PY - 2026
DA - 2026/10/21
JO - Frontiers in Pediatrics
DO - 10.3389/fped.2026.1854263
UR - https://doi.org/10.3389/fped.2026.1854263
AB - Objective: This study aimed to investigate the haematological changes in children with Mycoplasma pneumoniae (MP) infection carrying the 2063/2064 mutation, providing a clinical reference for the early identification of drug-resistant MP. Methods: A retrospective study was conducted on 161 children diagnosed with MP infection via nucleic acid testing in our hospital in 2024, alongside 27 healthy controls. Based on the 2063/2064 mutation status, the MP group was divided into a mutation-undetected group (n = 27) and a mutation-detected group (n = 134). Haematological parameters and inflammatory indices at diagnosis were compared. Dynamic changes between the initial visit and diagnosis were analysed in 64 mutation-detected patients with complete paired data. Additional analyses included bootstrap resampling, post-hoc power assessment, exploratory ROC analysis, logistic regression and hospitalisation-stratified sensitivity analysis. Results: No significant differences were observed between the mutation-detected and mutation-undetected groups in clinical characteristics or haematological and inflammatory indices at diagnosis (all p > 0.05). Among the 64 mutation-detected patients with complete paired measurements, MLR decreased from 0.32 (0.24, 0.48) at the initial visit to 0.27 (0.19, 0.37) at diagnosis (p = 0.004). In the hospitalisation-stratified analysis, this decline was significant among hospitalised patients but not among non-hospitalised patients. Exploratory ROC analysis showed limited discriminatory performance for both the directional MLR change (AUC = 0.508, 95% CI 0.344–0.672) and its absolute magnitude (AUC = 0.523, 95% CI 0.349–0.699). Conclusion: Static haematological parameters and inflammatory indices did not distinguish mutation-detected from mutation-undetected MP infection. Although MLR decreased over time in the mutation-detected subgroup, ROC and stratified analyses showed that this change had limited discriminatory performance when used alone and may have been influenced by hospitalisation-related clinical factors. Dynamic MLR change should therefore be considered an exploratory marker requiring prospective validation.
SN - 2296-2360
ER -